Cargando…

Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets

Skin cancer, which includes the most frequent malignant non-melanoma carcinomas (basal cell carcinoma, BCC, and squamous cell carcinoma, SCC), along with the difficult to treat cutaneous melanoma (CM), pose important worldwide issues for the health care system. Despite the improved anti-cancer armam...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobre, Elena-Georgiana, Constantin, Carolina, Neagu, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323323/
https://www.ncbi.nlm.nih.gov/pubmed/35887633
http://dx.doi.org/10.3390/jpm12071136
_version_ 1784756522299949056
author Dobre, Elena-Georgiana
Constantin, Carolina
Neagu, Monica
author_facet Dobre, Elena-Georgiana
Constantin, Carolina
Neagu, Monica
author_sort Dobre, Elena-Georgiana
collection PubMed
description Skin cancer, which includes the most frequent malignant non-melanoma carcinomas (basal cell carcinoma, BCC, and squamous cell carcinoma, SCC), along with the difficult to treat cutaneous melanoma (CM), pose important worldwide issues for the health care system. Despite the improved anti-cancer armamentarium and the latest scientific achievements, many skin cancer patients fail to respond to therapies, due to the remarkable heterogeneity of cutaneous tumors, calling for even more sophisticated biomarker discovery and patient monitoring approaches. Droplet digital polymerase chain reaction (ddPCR), a robust method for detecting and quantifying low-abundance nucleic acids, has recently emerged as a powerful technology for skin cancer analysis in tissue and liquid biopsies (LBs). The ddPCR method, being capable of analyzing various biological samples, has proved to be efficient in studying variations in gene sequences, including copy number variations (CNVs) and point mutations, DNA methylation, circulatory miRNome, and transcriptome dynamics. Moreover, ddPCR can be designed as a dynamic platform for individualized cancer detection and monitoring therapy efficacy. Here, we present the latest scientific studies applying ddPCR in dermato-oncology, highlighting the potential of this technology for skin cancer biomarker discovery and validation in the context of personalized medicine. The benefits and challenges associated with ddPCR implementation in the clinical setting, mainly when analyzing LBs, are also discussed.
format Online
Article
Text
id pubmed-9323323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93233232022-07-27 Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets Dobre, Elena-Georgiana Constantin, Carolina Neagu, Monica J Pers Med Review Skin cancer, which includes the most frequent malignant non-melanoma carcinomas (basal cell carcinoma, BCC, and squamous cell carcinoma, SCC), along with the difficult to treat cutaneous melanoma (CM), pose important worldwide issues for the health care system. Despite the improved anti-cancer armamentarium and the latest scientific achievements, many skin cancer patients fail to respond to therapies, due to the remarkable heterogeneity of cutaneous tumors, calling for even more sophisticated biomarker discovery and patient monitoring approaches. Droplet digital polymerase chain reaction (ddPCR), a robust method for detecting and quantifying low-abundance nucleic acids, has recently emerged as a powerful technology for skin cancer analysis in tissue and liquid biopsies (LBs). The ddPCR method, being capable of analyzing various biological samples, has proved to be efficient in studying variations in gene sequences, including copy number variations (CNVs) and point mutations, DNA methylation, circulatory miRNome, and transcriptome dynamics. Moreover, ddPCR can be designed as a dynamic platform for individualized cancer detection and monitoring therapy efficacy. Here, we present the latest scientific studies applying ddPCR in dermato-oncology, highlighting the potential of this technology for skin cancer biomarker discovery and validation in the context of personalized medicine. The benefits and challenges associated with ddPCR implementation in the clinical setting, mainly when analyzing LBs, are also discussed. MDPI 2022-07-13 /pmc/articles/PMC9323323/ /pubmed/35887633 http://dx.doi.org/10.3390/jpm12071136 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dobre, Elena-Georgiana
Constantin, Carolina
Neagu, Monica
Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
title Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
title_full Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
title_fullStr Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
title_full_unstemmed Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
title_short Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets
title_sort skin cancer research goes digital: looking for biomarkers within the droplets
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323323/
https://www.ncbi.nlm.nih.gov/pubmed/35887633
http://dx.doi.org/10.3390/jpm12071136
work_keys_str_mv AT dobreelenageorgiana skincancerresearchgoesdigitallookingforbiomarkerswithinthedroplets
AT constantincarolina skincancerresearchgoesdigitallookingforbiomarkerswithinthedroplets
AT neagumonica skincancerresearchgoesdigitallookingforbiomarkerswithinthedroplets